Literature DB >> 10195764

Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice.

R Zurbriggen1, R Glück.   

Abstract

The immunogenicity and protectivity of two different toxoid vaccines were compared in mice. In one formulation, toxoids (diphtheria or tetanus) were adsorbed to alumoxid, whereas in the other formulation the toxoids were crosslinked to immunopotentiating reconstituted influenza virosomes (IRIVs). A preimmunization with influenza antigens is necessary for a good anti-toxoid antibody response when the IRIV formulation was administered. After two immunizations with the IRIV- or alum-based vaccines, the IRIV-based formulation induced a higher humoral immune response than toxoids adsorbed to alum. Using an in vitro test, diphtheria toxin neutralizing antibodies were tested. Di-IRIV induced a significantly (p = 0.002) higher titer of diphtheria toxin neutralizing antibodies than Di-alum. Tetanus challenge experiments showed, that the IRIV-based tetanus vaccine induced a threefold higher titer of protective antibodies than the tetanus toxoid adsorbed to alum. Therefore, the IRIV-based formulations appeared to be superior to the alum-based vaccines in terms of immunogenicity and protectivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195764     DOI: 10.1016/s0264-410x(98)00361-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

Review 2.  Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.

Authors:  Nicole Westerfeld; Gerd Pluschke; Rinaldo Zurbriggen
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

3.  Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.

Authors:  F Pöltl-Frank; R Zurbriggen; A Helg; F Stuart; J Robinson; R Glück; G Pluschke
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

Review 4.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

5.  Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice.

Authors:  B Garulli; G Di Mario; M G Stillitano; D Compagnoni; F Titti; A Cafaro; B Ensoli; Y Kawaoka; M R Castrucci
Journal:  Biomed Res Int       Date:  2014-05-14       Impact factor: 3.411

6.  Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice.

Authors:  Ruonan Bo; Yaqin Sun; Shuzhen Zhou; Ning Ou; Pengfei Gu; Zhenguang Liu; Yuanliang Hu; Jiaguo Liu; Deyun Wang
Journal:  Int J Nanomedicine       Date:  2017-08-28

7.  Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.

Authors:  Rebecca A M Blom; Mario Amacker; R Maarten van Dijk; Christian Moser; Philip A Stumbles; Fabian Blank; Christophe von Garnier
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.